Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Alternative Names: AT 9311; AT1772; AT2035; AT3424; AT381; AT3851; LCQ 195; NVP-LCQ195

Latest Information Update: 25 Jul 2011

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics
  • Class Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Dec 2005 AT 9311 has been licensed to Novartis worldwide
  • 12 Sep 2005 AT 7519 has advanced from this programme into clinical development
  • 29 Nov 2004 Data presented at the British Cancer Research Meeting 2004 (BCRM 2004) have been added to the pharmacokinetics and Cancer pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top